Last reviewed · How we verify
RiBVD
At a glance
| Generic name | RiBVD |
|---|---|
| Sponsor | French Innovative Leukemia Organisation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma (PHASE2)
- Study of Mantle Cell Lymphoma Treatment by RiBVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RiBVD CI brief — competitive landscape report
- RiBVD updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI